Actemra

Rheumatoid arthritis (RA) is a progressive, systemic autoimmune disease characterised by chronic inflammation of multiple joints, pain and fatigue. Breakthrough research on targeting the inflammatory cascade led scientists to identify interleukin-6 (IL-6) as a key player in the development of this disease.

What is Actemra?

Actemra (tocilizumab) is the first humanised interleukin-6 (IL-6) receptor inhibiting
monoclonal antibody and represents a novel mechanism of action to treat RA.¹